➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Dow
McKinsey
Boehringer Ingelheim
Medtronic

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,227,507


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,227,507 protect, and when does it expire?

Patent 8,227,507 protects AKLIEF and is included in one NDA.

This patent has twenty-three patent family members in twenty countries.

Summary for Patent: 8,227,507
Title:Ligands that modulate RAR receptors
Abstract: Novel ligand compounds having the general formula (I): ##STR00001## and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.
Inventor(s): Biadatti; Thibaud (Opio, FR), Dumais; Laurence (La Rouret, FR), Soulet; Catherine (Antibes, FR), Talano; Sandrine (Vence, FR), Daver; Sebastien (Antibes, FR)
Assignee: Galderma Research & Development (Biot, FR)
Application Number:12/842,347
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Recent additions to Drugs Protected by US Patent 8,227,507

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Galderma Labs Lp AKLIEF trifarotene CREAM 211527 Oct 4, 2019 RX Yes   Start Trial   Start Trial U-818 TOPICAL TREATMENT OF ACNE VULGARIS
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,227,507

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp AKLIEF trifarotene CREAM;TOPICAL 211527-001 Oct 4, 2019 RX Yes Yes   Start Trial   Start Trial TOPICAL TREATMENT OF ACNE VULGARIS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,227,507

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France04 13848Dec 23, 2004

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKinsey
Colorcon
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.